Advestra advised the banking syndicate on Molecular Partners AG’s Initial Public Offering in the United States and its listing on NASDAQ raising gross proceeds of approximately USD 63.8 million. Molecular Partners is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics. As part of this transaction Molecular Partners offered 3,000,000 American Depositary Shares in the United States at a public offering price of USD 21.25 per ADS. Each ADS represents one new ordinary share issued by Molecular Partners out of its authorized share capital. Molecular Partner’s ordinary shares continue to be listed and traded on SIX Swiss Exchange.
J.P. Morgan SE, SVB Leerink and Cowen acted as joint book-running managers for the offering. RBC Capital Markets acted as the bookrunner, Kempen & Co as the lead manager for the offering.
Advestra acted as Swiss legal counsel to the banking syndicate. The team included Alexander von Jeinsen, Thomas Reutter and Fabian Loretan (all Capital Markets) and Laurent Riedweg (Tax).